Atezolizumab (MPDL3280A, an investigational engineered anti-PDL1 antibody)
Trials are currently recruiting in various tumor types*
- •NCT02409355
- •NCT02409342
- •NCT02367794
- •NCT02367781
- •NCT02366143
- •NCT02013219
- •NCT02291289
- •NCT02431208
- •NCT02220842
- •NCT02323191
- •NCT02304393
- •NCT01633970
- •NCT02410512
- •NCT02174172
- •NCT01375842
LOCATE TRIAL
›››
*All trials consistent with information on ClinicalTrials.gov as of May 26, 2015.